ACADIA to Host Conference Call and Webcast on Tuesday, February 27,
2018, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Feb. 20, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the fourth
quarter and year ended December 31, 2017 on Tuesday, February 27, 2018,
after the U.S. financial markets close. ACADIA's management will host a
conference call and webcast on Tuesday, February 27, 2018, at 5:00 p.m.
Eastern Time to discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for
participants in the United States or Canada and 830-865-2550 for
international callers (reference passcode 8377668). A telephone replay
of the conference call may be accessed through March 13, 2018 by dialing
855-859-2056 for callers in the United States or Canada and 404-537-3406
for international callers (reference passcode 8377668). The conference
call also will be webcast live on ACADIA’s website, www.acadia-pharm.com
under the investors section and will be archived there until March 13,
2018.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines that address unmet medical needs in central nervous system
disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release
that are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to statements
related to the progress and timing of ACADIA’s drug discovery and
development programs, and the benefits to be derived from NUPLAZID®
(pimavanserin) and ACADIA’s product candidates. These statements are
only predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or results
may differ materially from those projected in any of such statements due
to various factors, including the risks and uncertainties inherent in
drug discovery, development, approval and commercialization, and in
collaborations with others, and the fact that past results of clinical
trials may not be indicative of future trial results. For a discussion
of these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended December 31, 2016 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180220005518/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Investor
Relations
(858) 558-2871
[email protected]